Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Reiterated by HC Wainwright

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $13.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 88.13% from the company’s current price.

Aurinia Pharmaceuticals Stock Performance

AUPH opened at $6.91 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.33 and a quick ratio of 4.82. The business has a fifty day simple moving average of $5.88 and a 200 day simple moving average of $5.51. Aurinia Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $10.24. The company has a market capitalization of $985.81 million, a PE ratio of -16.07 and a beta of 1.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The company had revenue of $57.10 million during the quarter, compared to analysts’ expectations of $54.25 million. During the same quarter in the previous year, the business posted ($0.08) earnings per share. Aurinia Pharmaceuticals’s quarterly revenue was up 37.6% on a year-over-year basis. Research analysts expect that Aurinia Pharmaceuticals will post 0.13 EPS for the current year.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, insider Scott Michael Habig sold 18,249 shares of Aurinia Pharmaceuticals stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total value of $96,902.19. Following the completion of the transaction, the insider now directly owns 456,338 shares of the company’s stock, valued at approximately $2,423,154.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Large investors have recently bought and sold shares of the company. Stonepine Capital Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $1,713,000. B. Riley Wealth Advisors Inc. bought a new stake in Aurinia Pharmaceuticals during the second quarter worth $84,000. Algert Global LLC lifted its stake in Aurinia Pharmaceuticals by 106.8% during the second quarter. Algert Global LLC now owns 193,804 shares of the biotechnology company’s stock worth $1,107,000 after purchasing an additional 100,104 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Aurinia Pharmaceuticals by 10.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock valued at $301,000 after purchasing an additional 4,808 shares in the last quarter. Finally, AQR Capital Management LLC bought a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at $1,155,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.